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Abstract
Background: Myc-induced lymphoblastic B-cell lymphoma (LBL) in iMycEµ mice may provide a model system for the
study of the mechanism by which human MYC facilitates the initiation and progression of B cell and plasma cell neoplasms
in human beings. We have recently shown that gene-targeted iMycEµ mice that carry a His6-tagged mouse Myc cDNA,
MycHis, just 5' of the immunoglobulin heavy-chain enhancer, Eµ, are prone to B cell and plasma cell tumors. The
predominant tumor (~50%) that arose in the iMycEµ mice on the mixed genetic background of segregating C57BL/6 and
129/SvJ alleles was LBL. The purpose of this study was to establish and characterize a cell line, designated iMycEµ-1, for
the in-depth evaluation of LBL in vitro.
Methods: The morphological features and the surface marker expression profile of the iMycEµ-1 cells were evaluated
using cytological methods and FACS, respectively. The cytogenetic make-up of the iMycEµ-1 cells was assessed by spectral
karyotyping (SKY). The expression of the inserted MycHis gene was determined using RT-PCR and qPCR. Clonotypic
immunoglobulin gene arrangements were detected by Southern blotting. The global gene expression program of the
iMycEµ-1 cells and the expression of 768 "pathway" genes were determined with the help of the Mouse Lymphochip© and
Superarray© cDNA micro- and macroarrays, respectively. Array results were verified, in part, by RT-PCR and qPCR.
Results: Consistent with their derivation from LBL, the iMycEµ-1 cells were found to be neoplastic IgM highIgDlow
lymphoblasts that expressed typical B-cell surface markers including CD40, CD54 (ICAM-1), CD80 (B7-1) and CD86
(B7-2). The iMycEµ-1 cells harbored a reciprocal T(9;11) and three non-reciprocal chromosomal translocations, over-
expressed  MycHis at the expense of normal Myc, and exhibited gene expression changes on Mouse Lymphochip©
microarrays that were consistent with MycHis-driven B-cell neoplasia. Upon comparison to normal B cells using eight
different Superarray© cDNA macroarrays, the iMycEµ-1 cells showed the highest number of changes on the NFκB array.
Conclusion:  The iMycEµ-1 cells may provide a uniquely useful model system to study the growth and survival
requirements of Myc-driven mouse LBL in vitro.
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Background
Gene-targeted iMycEµ mice contain a single-copy mouse
MycHis (c-myc) cDNA that has been inserted in opposite
transcriptional orientation in the mouse immunoglobu-
lin heavy-chain gene cluster, Igh. The specific insertion site
of the MycHis transgene is in the intervening region of the
Igh joining gene locus, JH, and the intronic heavy-chain
enhancer, Eµ. The inserted transgene encodes a C-termi-
nal His6 tag that is useful to distinguish message and pro-
tein encoded by MycHis and normal Myc [1]. The iMycEµ
mice provide a model system for the study of the molecu-
lar and oncogenic consequences of the human MYC- and
mouse Myc-deregulating chromosomal t(8;14)(q24;q32)
and T(12;15) translocations that are widely accepted as
the crucial initiating oncogenic events in the great major-
ity of human Burkitt lymphomas (BL) and mouse plasma-
cytomas, respectively [2]. Specifically, the iMycEµ mice
mimic the type of t(8;14)(q24;q32) and T(12;15) translo-
cation that is found in the endemic form of BL [3] and a
subset (~20%) of IL-6 transgenic mouse plasmacytomas
[4], respectively. We have recently shown that hetero-
zygous transgenic iMycEµ mice on the mixed genetic back-
ground of segregating C57BL/6 and 129/SvJ alleles are
genetically prone to mature B cell and plasma cell neo-
plasms, ~50% of which are IgM+ lymphoblastic B-cell
lymphomas (LBL) [1]. We now report on a newly estab-
lished LBL-derived cell line, iMycEµ-1, which was devel-
oped to study the growth and survival requirements of
LBL in vitro.
Results and Discussion
Features of iMycEµ-1 cells
The iMycEµ-1 cell line, which demonstrated the typical
cytological features of mouse LBL (Fig. 1A top), was
derived from a primary IgM+LBL (Fig. 1A bottom) that
exhibited moderate plasmacytic differentiation potential
in situ (not shown). FACS analysis using a panel of anti-
bodies to B cell surface markers (Fig. 1B) showed that
iMycEµ-1 cells were positive for CD40, CD48, CD54,
Features of iMycEµ-1 cells Figure 1
Features of iMycEµ-1 cells. A, cytofuge specimen of cultured cells stained according to May-Grünwald-Giemsa (top). Tissue 
section of the LBL from which the cell line was derived after immunostaining for µ H-chain (bottom). B, B-cell surface marker 
expression evaluated by FACS in cells treated with specific antibodies (purple histograms) or isotype controls (green lines). C, 
H/L rearrangements and surface Ig expression. Southern blots of Igh (top left) and Igk (top right) rearrangements of the LBL 
from which the cell line was derived. Included as control is liver DNA from homozygous (Tg/Tg) or heterozygous (Tg/+) trans-
genic iMycEµ mice (left panel) or inbred C57BL/6 and 129SvJ mice (right panel). Recombination at the Igh locus was detected by 
the reduction of the normal, H chain-encoding upper fragment (upper arrowhead) in the face of comparable amounts of the 
mutated, MycHis-harboring lower fragment (lower arrowhead). Thus, the 6.2 kb long upper fragment was diminished in the LBL 
compared to the Tg/+ sample (and absent, as expected, in the Tg/Tg sample), whereas the MycHis-harboring lower fragment 
was comparable. The MycHis-bearing Igh locus cannot encode H chain because of the gene insertion. Recombination at the Igκ 
locus resulted in an enlarged fragment (~7.8 kb) compared to the germ line fragment that is indicated by the arrowhead point-
ing left. Detection of surface IgMhiIgDlow using FACS analysis (bottom).Molecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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CD80/86 (B7-1/2) and CD138 (syndecan 1). Expression
of class I and II MHC antigens and CD45 (B220) was
detectable at low or very low levels, respectively, but
CD95 (Fas) was absent. Treatment of iMycEµ-1 cells with
antibody to CD40 led to the induction of Fas and upregu-
lation of CD45 and CD54, activation markers CD80/86,
and CD138, indicating that CD40 signaling was func-
tional (Additional File 1). Southern blotting of genomic
DNA from the LBL from which the cell line was derived
demonstrated V(D)J rearrangement at the Ig heavy-chain
and κ light chain loci (Fig. 1C top). The expression of sur-
face IgMhighIgDlow by the derivative cell line was consistent
with this and indicated that the rearrangement was pro-
ductive (Fig. 1C bottom). SKY analysis of metaphase chro-
mosomes from iMycEµ-1 cells (Fig. 2) uncovered four
chromosomal translocations that took the form of a recip-
rocal T(9;11) exchange and three non-reciprocal
exchanges: T(13;16), T(14;13) and T(17;6). Although it is
unclear whether these translocations occurred during
tumor development or establishment of the cell line [5],
repeat karyotyping showed that the present iMycEµ-1 line
is cytogenetically stable.
Spectral karyotype of iMycEµ-1 cells Figure 2
Spectral karyotype of iMycEµ-1 cells. A, representative metaphase chromosome spread in SKY display (left) and classifica-
tion colors (center) and as an inverted DAPI image (right). B, complete, near-diploid tumor karyotype depicting each chromo-
some in SKY display (left) and classification (right) colors and after staining with DAPI (center): 38–40, XX, Del(4)(C4)[2], 
Del(6)(D2)[6], Der(9)T(9A4;11E2)[4], Der(11)T(11A4;9E4)[4], Del(12)[3], Der(13)T(13D11;16B5)[5], Der(14)T(14;13)[3], 
Der(17) T(17D;6D3)[5], +19[6]. The chromosomes are arranged in numerical order from left to right and top to bottom. C, 
chromosomal translocations that took the form of a reciprocal T(9;11) exchange (left) and three different non-reciprocal 
exchanges (right).Molecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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Similar gene expression profile of iMycEµ-1 cells and LBL using comparative cDNA microarray measurements Figure 3
Similar gene expression profile of iMycEµ-1 cells and LBL using comparative cDNA microarray measurements. Relative gene 
expression levels are depicted according to the color scale shown below the cluster.Molecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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Myc expression and Myc-driven gene expression changes in iMycEµ-1 cells Figure 4
Myc expression and Myc-driven gene expression changes in iMycEµ-1 cells. A, expression of Myc in iMycEµ-1 cells, 
LBL, and normal controls. The average gene expression was calculated and plotted according to the microarray measurements 
shown in Figure 3. B, RT-PCR of Myc, MycHis and Aktb mRNA levels (top) and Western blotting of Myc protein (bottom) in nor-
mal B cells (lane 1), LBL from an iMycEµ mouse (lane 2), and the iMycEµ-1 cell line (lane 3; SM, size marker). C, real-time qPCR 
analysis of Myc mRNA levels in iMycEµ-1 and LBL cells. Mean values and standard deviations based on three independent 
iMycEµ-1 and five LBL samples are shown. D, expression of proliferation signature genes in iMycEµ samples and normal controls. 
The expression of genes that fall in the proliferation signature defined in Figure 3 was averaged for each cell population and 
plotted. E, differentially expressed Myc targets in iMycEµ-1 cells (left column) and LBL (right column) compared to normal rest-
ing B cells. Relative gene expression levels are depicted according to the color scale at the bottom. Gene designations and 
names are listed to the right.Molecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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Gene expression profile of iMycEµ-1 cells on cDNA 
microarray
The Mouse Lymphochip, a microarray of hematopoietic
mouse cDNA clones, provides a powerful tool to evaluate
the similarity of primary mouse B cells, B-cell tumors, and
tumor-derived cell lines at the level of global gene expres-
sion [6]. To compare the gene expression profile of LBL
and iMycEµ-1 cells, RNA was obtained from primary B
cells, fresh-frozen tumors and iMycEµ-1 cells. The RNA was
labeled with Cy5-dUTP, and hybridized to the cDNA
microarray spotted on a glass slide. An RNA control pool
labeled with Cy3-dUTP was co-hybridized to the same
array and used as a common denominator by which all
samples were compared to one another. Further informa-
tion on microarray make-up, analysis and data interpreta-
tion is available at: http://lymphochip.nih.gov/
ShafferPCfactors/.
Three independent RNA samples of iMycEµ-1 cells and ten
primary LBL were analyzed together with a collection of
normal, resting mouse B cells and T cells, mouse embry-
onic fibroblasts (MEF), and peritoneal plasmacytomas
that arose in pristane-treated BALB/c mice. A total of 414
well-characterized array elements that clustered across
these samples based on gene expression patterns (Fig. 3)
demonstrated a clear distinction of lymphoid and non-
lymphoid cell types (B and T cells versus MEF), lym-
phocyte lineages (B versus T cells), and transformation-
and development-associated differences within the B-cell
lineage (normal B cells versus LBL and PCT). The gene
expression profiles of LBL and iMycEµ-1 cells, which clus-
tered in one tight group (Fig. 3 top, blue rectangle), exhib-
ited a remarkable homogeneity. Compared to the
plasmacytomas, LBL and iMycEµ-1 cells maintained many
hallmark genes in the B cell signature (e.g., those encod-
ing CD19, CD79 and µ heavy-chain) but under-expressed
numerous genes in the plasma cell signature (e.g., Sec61,
Ssr4 and DNAjc3) and matrix signature (e.g., those encod-
ing vinculin, gelsolin and integrin B1) [7,8]. A more
detailed analysis of the plasma cell signature revealed that
in contrast to Xbp1 and its target genes, the iMycEµ-1 cells
expressed Prdm1 (Blimp1). This suggested that the cells
underwent neoplastic transformation at the early stage of
plasmacytic differentiation (Additional File 2).
Myc expression in LBL and iMycEµ-1 cells
The expression levels of Myc, as measured by the arrays,
was clearly elevated in LBL and iMycEµ-1, intermediate in
"premalignant" B cells from tumor-free iMycEµ mice, and
absent, as expected, in resting lymphocytes from normal
mice (Fig. 4A). Because the inserted Myc cDNA in iMycEµ
mice also encodes a C-terminal His6 tag, it is possible to
distinguish message and protein encoded by MycHis and
normal Myc. Allele-specific RT-PCR analysis of MycHis and
Myc mRNA demonstrated that, in common with LBL,
iMycEµ-1 cells expressed predominantly the transgene
(Fig. 4B top, lanes 2–3). This pattern of suppression of the
normal Myc gene [9] is also a feature of human B-cell lym-
phomas containing constitutively deregulated MYC [10].
Western blotting with an anti-Myc antibody detecting
both MycHis and normal Myc proteins (Fig. 4B bottom)
showed that LBL and iMycEµ-1 cells over-expressed Myc at
comparable levels (lanes 2–3) relative to B splenocytes
from non-transgenic littermates (lane 1). To compare the
levels of Myc in LBL and iMycEµ-1 cells more precisely, we
performed qPCR using Aktb mRNA levels as internal
standard. The iMycEµ-1 cells expressed nearly twice as
much Myc as the LBL (Fig. 4C). The levels of Myc also cor-
related with the expression of genes from the proliferation
cluster when the gene expression from the proliferation
signature, as defined in Figure 3, was averaged for each cell
type. Proliferation gene expression was low in unstimu-
lated cells (MEF and B/T cell samples), intermediate in
pre-malignant B cells from iMycEµ mice, and upregulated
in LBL and iMycEµ-1 (Fig. 4D).
Myc target genes in LBL and iMycEµ-1 cells
To further examine the contribution of the MycHis trans-
gene to the gene expression profile of LBL and iMycEµ-1,
we performed a statistical analysis (Student's T test) of
genes differentially expressed between normal B cells ver-
sus LBL and iMycEµ-1 cells. A total of 122 array elements
from Figure 3 were significantly differential in their
expression when B cells were compared to iMycEµ-1 cells
and LBL (p < 0.015, 1.5-fold minimal difference in aver-
age expression). The vast majority (97%) of these ele-
ments, many of them previously identified as
proliferation-associated Myc targets http://www.myc-can-
cer-gene.org, behaved similarly in both the cell line and
LBL (Fig. 4E). Twenty-four known Myc targets were up-
regulated in the LBL and iMycEµ-1 cells (Ahcy, Apex1,
Cbfb, Cdk4, Ctps, Eef2, Gapd, Hdgf, Hnrpa1, Hnrpd,
Idh1, Myc, Ncl, Nme1, Npm1, Pa2g4, Pcna, Pim1, Pkm2,
Ppia, Sfrs2Slc7a5, Tfdp1), two were down-regulated
(Btg1, Igk), and five were undetermined as to the effect of
Myc on their expression (Aldh2, Hint1, Mcl1, Rheb,
Slc1a4). These findings were in accordance with the
nature of LBL and iMycEµ-1 as Myc-driven B-cell tumors
and firmly established the similarity of LBL and iMycEµ-
1at the level of a single gene (Fig. 4A), a gene expression
signature (Fig. 4D), and globally (Fig. 3).
Validation of gene expression changes in iMycEµ-1 cells
To further compare the gene expression profiles of LBL
and iMycEµ-1, and validate the cDNA microarray results
with an independent method, we used cDNA macroarrays
on nylon membranes to assess the expression of selected
"pathway" genes in LBL, iMycEµ-1 and normal B cells.
Included in the analysis were RNA samples of iMycEµ-1
and LBL previously analyzed on the microarray. FreshlyMolecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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Concordant gene expression changes in iMycEµ-1 cells and LBL compared to normal B cells Figure 5
Concordant gene expression changes in iMycEµ-1 cells and LBL compared to normal B cells. A, gene expression 
changes were assessed by comparative filter cDNA macroarray measurements using a representative apoptosis array of nor-
mal B cells (left), LBL (center) and iMycEµ-1 cells (right) as the example. Compared to B cells, LBL and iMycEµ-1 cells under-
expressed Bcl2a1d (array position D2), Birc2 (G3), Cflar (G4), Ripk1 (G8) and Traf5 (E12; indicated by green squares). Addi-
tional File 3 shows four additional LBL arrays that exhibit the same changes. B, expression changes of 5 up-regulated and 11 
down-regulated genes in iMycEµ-1 cells compared to normal B cells (see Additional File 6 for names, functions and groupings of 
these genes). Similar changes were seen when LBL and B cells were compared using cDNA macroarrays (not shown) or when 
iMycEµ-1 cells and/or LBL were compared to B cells using cDNA microarrays (Fig. 3; results not shown). C, verification of gene 
array results using RT-PCR. Shown are ethidium bromide-stained PCR fragments of the differentially regulated genes plotted in 
panel B except Myc, which was verified in the experiments presented in Figure 4A-C. The iMycEµ-1 and B-cell samples are 
shown in the right and left lane, respectively. Up and down regulated genes are depicted on the pink and green background, 
respectively.Molecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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prepared RNA from normal, MACS purified, B220+ splen-
ocytes were used as control. RNA samples were labeled
with 32P-dUTP and individually hybridized to the mac-
roarrays. Individual expression profiles were determined
and compared with each other. Reproducible two-fold or
higher changes in hybridization signal intensity were used
as threshold for gene expression changes. Eight different
macroarrays, each containing 96 genes involved in cell
cycle regulation, apoptosis, cancer, signal transduction,
stress and toxicity responses, and the NFκB and MAPK
pathways, were used. The primary data set is depicted in
Additional File 3.
The changes on the macroarrays were remarkably consist-
ent in LBL and iMycEµ-1 cells compared to B cells. This is
illustrated in Figure 5A, using the apoptosis array as the
example. Among a total of 768 genes present on eight dif-
ferent macroarrays, 121 (16%) genes were concordantly
up- or down-regulated in LBL and iMycEµ-1 cells relative
to B cells. The NFκB array showed the highest number of
changes (n = 22) among the eight different macroarrays,
followed by the MAPK (n = 19), cell cycle (n = 18) and
apoptosis arrays (n = 17). The stress and toxicity array con-
tained the lowest number of changes (n = 9). Altogether,
down-regulated genes (83/121, 69%) outnumbered up-
regulated genes (38/121, 31%) by a factor of 2.2. The
presence of some genes on two or more arrays afforded an
opportunity for additional quality control. Genes of that
sort exhibited the same trend on different arrays, either up
or down relative to normal B cells, thus adding confidence
in the results. This is illustrated in Additional File 4 using
one representative array each of iMycEµ-1 and normal B
cells.
Among the differentially regulated genes that exhibited
concordant changes in LBL and iMycEµ-1 cells relative to
normal B cells on both the gene micro- and macroarrays
were 16 genes that were selected for further confirmation
using semi-quantitative RT-PCR (Additional File 5). These
genes were of particular interest to us because of possible
follow-up studies on signaling pathways in iMycEµ-1 cells.
Eleven of the 16 genes were down regulated (Bcl2a1,
Birc2, Cflar, Cdkn1b, Grb2, Irf1, Jun, Map2k1, Rb1, Ripk1,
Traf5) and five genes were up regulated (Ccna2, Ccnb,
Myc, Nfkb1, Odc). Figure 5B presents average quantitative
changes on the macroarrays when iMycEµ-1 cells were
compared with normal B cells. These changes were readily
confirmed by RT-PCR in all cases (Fig. 5C) except Myc,
which was not included because it was confirmed in pre-
vious work (Fig. 4).
Conclusion
This study reports the molecular, cytogenetic and mor-
phological features of a stable cell line, designated iMycEµ-
1. The iMycEµ-1 cells are surface IgMhighIgDlow and cytoge-
netically stable using SKY. The cells express high levels of
the inserted MycHis transgene and exhibit a global gene
expression profile consistent with that of MycHis-driven B-
cell neoplasia. The iMycEµ-1 cells may be useful for in-
depth studies on the growth and survival requirements of
MycHis-driven mouse B-cell tumors in vitro. Specifically,
the cells may facilitate the elucidation of the signal trans-
duction pathways that appear to maintain high Myc pro-
tein levels in mouse LBL [1]. These studies may results in
new approaches to treat and prevent MYC-induced B cell
and plasma cell neoplasms in human beings.
Methods
Mouse lymphomas and derivation of iMycEµ-1 cells
Transgenic iMycEµ mice develop a high incidence of B cell
and plasma cell tumors with LBL being the predominant
phenotype (8). Tumor samples obtained at autopsy were
fixed in formalin for later histopathology or frozen for
later preparation of protein, DNA and RNA. Histological
criteria used for diagnosing mouse LBL are detailed else-
where [11]. Highly enriched splenic B cells were prepared
from C57BL/6 mice using CD45R (B220) microbeads and
MACS separation columns (Miltenyi Biotec, Auburn, CA).
All mice were maintained under Animal Study Protocol
LG-028. The iMycEµ-1 cell line was derived from a LBL and
maintained at 37°C and 5% carbon dioxide in RPMI 1640
medium supplemented with 10% fetal calf serum, 200
mM L-glutamine, 50 µM 2-mercaptoethanol and penicil-
lin/streptomycin (Gibco-BRL, Rockville, MD).
Characterization of iMycEµ-1 cells
For cytological analysis, cytofuge specimens were stained
according to May-Grünwald-Giemsa and inspected by
microscopy. For detection of chromosomal aberrations,
cells were analyzed by spectral karyotyping (SKY) as pre-
viously described [12]. For flow cytometry, single-cell sus-
pensions were stained and analyzed on a FACSort® using
the CELLQuest™ software (BD Pharmingen, San Diego,
CA). Rat anti-mouse CD16/CD32 was used to block FcγII
and FcγIII receptors. Antibodies to mouse CD45 (catalog
number 553076), CD80 (553766), Fas (CD90, 554255),
CD86 (553689), CD40 (553787), I-Ab (MHC class II,
553551), H-2Kb (MHC class I, 553569), CD48 (557483),
CD54 (553250), CD138 (553712), IgD (553438) and
IgM (53519) were purchased from BD Biosciences. For
the evaluation of surface marker changes upon ligation of
CD40, cells were incubated with rat anti-mouse CD40
(553787) using 3.5 µg antiboy per 5 × 105 cells. For South-
ern blot hybridization of clonotypic V(D)J rearrange-
ments, genomic DNA (20 µg) was digested with BamHI
and EcoRI, fractionated on a 0.7 % agarose gel, transferred
to a nylon membrane, and crosslinked under UV light.
Following pre-hybridization (Hybrisol I, Intergen) at
42°C, the membrane was hybridized to a 1.5-kb HindIII/
EcoRI fragment of Igh spanning JH2 and Eµ or to a 1.1-kbMolecular Cancer 2005, 4:40 http://www.molecular-cancer.com/content/4/1/40
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Cκ probe, which was generated by PCR using a primer
pair obtained from Dr. Michael Kuehl (NCI): 5'-GAT GCT
GCA CCA ACT GTA TCC A-3' and 5'-GGG GTG ATC AGC
TCT CAG CTT-3'. Probes were labeled with [32P]-CTP
using a random priming kit.
Allele-specific RT-PCR of Myc and MycHis mRNA
For semi-quantitative determination of Myc and MycHis
mRNA, total RNA was isolated using TRIzol (Sigma, St.
Louis, MO, USA). Double stranded cDNA was synthesized
from 1 µg of total RNA, using the AMV Reverse Tran-
scriptase kit (Roche, Indianapolis, IN). A common 5'
primer for both MycHis and Myc (5'-TCT CCA CTC ACC
AGC ACA AC-3') was combined with a specific 3' primer
for MycHis (5'-CCT CGA GTT AGG TCA GTT TA-3') and
Myc (5'-ATG GTG ATG GTG ATG ATG AC-3') to distin-
guish the two messages. Thermal cycling conditions were
as follows: 95°C for 5 min followed by 20 cycles of ampli-
fication at 57°C, 72°C and 95°C, each for 1 min. PCR
amplification of Aktb cDNA was performed as control
using the following primer pair: 5'-GCA TTG TTA CCA
ACT GGG AC-3' and 5'-AGG CAG CTC ATA GCT CTT CT-
3'. PCR products were analyzed by electrophoresis in 1%
agarose gel and visualized by staining with ethidium bro-
mide.
Real-time qPCR of Myc mRNA
For quantitative Taqman RT-PCR of Myc (Myc plus
MycHis), total RNA was isolated from cells using TRIzol
Reagent (Invitrogen). Serial dilutions of input RNA (100
ng - 1.56 ng) were analyzed in triplicates using the ABI
PRISM 7900HT sequence detector system, primers,
probes, and the Taqman One-Step RT-PCR Master Mix
Reagents kit, all purchased from Applied Biosystems. The
reaction mixture was held at 48°C for 30 min for reverse
transcription of RNA into cDNA. This was followed by
incubation at 95°C for 10 min to activate the Taq
polymerase. PCR amplification of cDNA was performed
for 40 cycles using the following cycling conditions: dena-
turing for 15 s at 95°C and annealing and extending for 1
min at 60°C. All samples were tested in triplicates, and
average values were used for quantification. Analysis was
performed using SDS v2.1 software (Applied Biosystems)
according to the manufacturer's instruction. Aktb was
used as internal reference gene. The comparative CT
method (∆∆CT) was used for quantification of gene
expression.
Gene microarray hybridization and analysis
cDNA made from total RNA (50 µg) from each tumor, pri-
mary cell sample, or iMycEµ-1 cells was labeled with cya-
nine 5-conjugated dUTP (Cy5). cDNA made from pooled
mouse cell line RNA (50 µg) was labeled with cyanine 3-
conjugated dUTP (Cy3) and used as reference. Microarray
hybridizations were performed on Mouse Lymphochip
microarrays [7]. After washing, the slides were scanned
using an Axon GenePix 4.0 scanner (Axon Instruments
Inc., Union City, CA). After normalization, those ele-
ments that failed to meet confidence criteria based on sig-
nal intensity and spot quality were excluded from
analysis. In addition, data were discarded for any gene for
which measurements were missing on >30% of the arrays
or were not sequence-verified. The Cy5:Cy3 intensity
ratios of the remaining spots were log2 transformed. To
compare normal samples, hierarchical cluster analysis was
performed using the Gene Cluster and Treeview programs
[8].
Gene macroarray hybridization and analysis
The relative mRNA expression of genes involved in regu-
lation of apoptosis, cell cycle progression, NFkB signaling,
and cellular stress and toxicity responses was analyzed
with GEArray (SuperArray Inc., Bethesda, MD) according
to the manufacturer's protocol. Cells were treated for 24
hrs with 0.4 mM and 1 mM CDDO-Im, respectively, fol-
lowed by preparation of total RNA using TriReagent
(Sigma). Five µg from each sample were reverse tran-
scribed into 32P-labeled cDNA using MMLV reverse tran-
scriptase (Promega, Madison, WI) and 32P-dCTP (NEN,
Boston, MA). The resulting cDNA probes were hybridized
to gene-specific cDNA fragments spotted in quadrupli-
cates on the GEArray membranes. After stringent washing
of the arrays, the signal of the hybridized spots was meas-
ured with a STORM PhosphorImager (Molecular Dynam-
ics, Sunnyvale, CA) and normalized to the signal of the
housekeeping gene Gapd. Array results on six CDDO-Im
inducible genes were validated using semi-quantitative
RT-PCR.
Gene array validation using RT-PCR
For semi-quantitative determination of mRNA levels,
total RNA was isolated and double stranded cDNA was
synthesized as described above for Myc. Information on
PCR primers and thermal cycling conditions is available
in Additional File 6. PCR products were analyzed by elec-
trophoresis in 1% agarose gel and visualized by staining
with ethidium bromide.
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